Cheryl Waters

10.2k total citations
107 papers, 5.0k citations indexed

About

Cheryl Waters is a scholar working on Neurology, Physiology and Cognitive Neuroscience. According to data from OpenAlex, Cheryl Waters has authored 107 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Neurology, 20 papers in Physiology and 16 papers in Cognitive Neuroscience. Recurrent topics in Cheryl Waters's work include Parkinson's Disease Mechanisms and Treatments (83 papers), Neurological disorders and treatments (41 papers) and Botulinum Toxin and Related Neurological Disorders (15 papers). Cheryl Waters is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (83 papers), Neurological disorders and treatments (41 papers) and Botulinum Toxin and Related Neurological Disorders (15 papers). Cheryl Waters collaborates with scholars based in United States, Canada and France. Cheryl Waters's co-authors include Stanley Fahn, Karen Marder, Melissa J. Nirenberg, Mark Lew, Elan D. Louis, Steven J. Frucht, Howard Andrews, Helen Mejia‐Santana, Juliette Harris and Blair Ford and has published in prestigious journals such as PLoS ONE, Brain and Neurology.

In The Last Decade

Cheryl Waters

104 papers receiving 4.8k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Cheryl Waters 3.7k 1.3k 1.0k 649 624 107 5.0k
Radu Constantinescu 3.8k 1.1× 1.3k 1.0× 929 0.9× 892 1.4× 595 1.0× 60 5.0k
J.J. Zarranz 3.1k 0.9× 1.4k 1.1× 1.1k 1.0× 743 1.1× 749 1.2× 76 4.1k
Lucien Côté 3.1k 0.8× 1.4k 1.2× 741 0.7× 752 1.2× 548 0.9× 59 4.8k
Juan Carlos Gómez‐Esteban 3.8k 1.0× 1.4k 1.1× 1.1k 1.0× 628 1.0× 721 1.2× 126 4.7k
Lars Forsgren 3.2k 0.9× 940 0.7× 985 0.9× 1.0k 1.6× 721 1.2× 101 4.9k
Roy N. Alcalay 3.5k 1.0× 975 0.8× 1.9k 1.8× 993 1.5× 860 1.4× 167 5.0k
Ruth Djaldetti 3.0k 0.8× 1.2k 0.9× 598 0.6× 760 1.2× 512 0.8× 129 4.7k
John E. Duda 4.2k 1.1× 1.5k 1.2× 1.6k 1.6× 749 1.2× 1.0k 1.6× 81 5.9k
Meike Kasten 2.5k 0.7× 1.1k 0.9× 537 0.5× 976 1.5× 692 1.1× 90 4.3k
Dirk Woitalla 2.3k 0.6× 993 0.8× 556 0.5× 944 1.5× 503 0.8× 112 3.8k

Countries citing papers authored by Cheryl Waters

Since Specialization
Citations

This map shows the geographic impact of Cheryl Waters's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheryl Waters with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheryl Waters more than expected).

Fields of papers citing papers by Cheryl Waters

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cheryl Waters. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheryl Waters. The network helps show where Cheryl Waters may publish in the future.

Co-authorship network of co-authors of Cheryl Waters

This figure shows the co-authorship network connecting the top 25 collaborators of Cheryl Waters. A scholar is included among the top collaborators of Cheryl Waters based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cheryl Waters. Cheryl Waters is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Senkevich, Konstantin, Eric Yu, Jamil Ahmad, et al.. (2024). Are rare heterozygous SYNJ1 variants associated with Parkinson’s disease?. npj Parkinson s Disease. 10(1). 201–201.
2.
Surface, Matthew, Manisha Balwani, Cheryl Waters, et al.. (2021). Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease. Movement Disorders. 37(2). 416–421. 28 indexed citations
3.
Yu, Eric, Lynne Krohn, Uladzislau Rudakou, et al.. (2021). LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease. Neurobiology of Aging. 103. 142.e1–142.e5. 15 indexed citations
4.
Rudakou, Uladzislau, Eric Yu, Lynne Krohn, et al.. (2020). Targeted sequencing of Parkinson’s disease loci genes highlights SYT11, FGF20 and other associations. Brain. 144(2). 462–472. 29 indexed citations
5.
Yu, Eric, Uladzislau Rudakou, Lynne Krohn, et al.. (2020). Analysis of Heterozygous PRKN Variants and Copy‐Number Variations in Parkinson's Disease. Movement Disorders. 36(1). 178–187. 29 indexed citations
6.
Saini, Prabhjyot, Uladzislau Rudakou, Eric Yu, et al.. (2020). Association study of DNAJC13, UCHL1, HTRA2, GIGYF2, and EIF4G1 with Parkinson's disease. Neurobiology of Aging. 100. 119.e7–119.e13. 25 indexed citations
7.
Farbman, Eric S., Cheryl Waters, Peter A. LeWitt, et al.. (2020). A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease. Parkinsonism & Related Disorders. 81. 144–150. 15 indexed citations
8.
Fischer, Tanya, Thomas Gasser, Stuart Isaacson, et al.. (2019). Safety, tolerability and pharmacokinetics of oral venglustat in Parkinson’s disease patients with a GBA mutation (S4.002). Neurology. 92(15_supplement). 3 indexed citations
9.
10.
11.
Rudakou, Uladzislau, Bouchra Ouled Amar Bencheikh, Jennifer A. Ruskey, et al.. (2018). Common and rare GCH1 variants are associated with Parkinson's disease. Neurobiology of Aging. 73. 231.e1–231.e6. 17 indexed citations
12.
Wang, Yuanjia, Lorraine N. Clark, Elan D. Louis, et al.. (2008). Risk of Parkinson Disease in Carriers of Parkin Mutations. Archives of Neurology. 65(4). 467–467. 32 indexed citations
13.
Poston, Kathleen L. & Cheryl Waters. (2007). Zydis selegiline in the management of Parkinson's disease. Expert Opinion on Pharmacotherapy. 8(15). 2615–2624. 8 indexed citations
14.
Levy, Gilberto, Elan D. Louis, Helen Mejia‐Santana, et al.. (2004). Lack of Familial Aggregation of Parkinson Disease and Alzheimer Disease. Archives of Neurology. 61(7). 1033–9. 32 indexed citations
15.
Waters, Cheryl, et al.. (2003). Hepatotoxic profile of catecholOmethyltranferase inhibitors in Parkinson’s disease. Expert Opinion on Drug Safety. 2(3). 263–267. 19 indexed citations
16.
Taylor, P. M., Sheilah A. Robertson, MJ Dixon, et al.. (2001). Morphine, pethidine and buprenorphine disposition in the cat. Journal of Veterinary Pharmacology and Therapeutics. 24(6). 391–398. 89 indexed citations
17.
Waters, Cheryl. (2001). Advances in Managing Parkinson's Disease. Hospital Practice. 36(6). 27–41. 1 indexed citations
18.
Sutton, James P., William T. Couldwell, Mark Lew, et al.. (1995). Ventroposterior Medial Pallidotomy in Patients with Advanced Parkinson's Disease. Neurosurgery. 36(6). 1134–1141. 122 indexed citations
19.
Waters, Cheryl, et al.. (1990). Utilization of unilateral and bilateral stereotactically placed adrenomedullary-striatal autografts in parkinsonian humans. Neurosurgery. 26(5). 746–746. 26 indexed citations
20.
Waters, Cheryl. (1988). Cognitive Enhancing Agents: Current Status in the Treatment of Alzheimer's Disease. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 15(3). 249–256. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Radu Constantinescu Breakdown of academic impact, for papers by J.J. Zarranz Breakdown of academic impact, for papers by Lucien Côté Breakdown of academic impact, for papers by Juan Carlos Gómez‐Esteban Breakdown of academic impact, for papers by Lars Forsgren Breakdown of academic impact, for papers by Roy N. Alcalay Breakdown of academic impact, for papers by Ruth Djaldetti Breakdown of academic impact, for papers by John E. Duda Breakdown of academic impact, for papers by Meike Kasten Breakdown of academic impact, for papers by Dirk Woitalla
Rankless by CCL
2026